Where AtriCure Stands With Analysts
Within the last quarter, AtriCure (NASDAQ:ATRC) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell
• GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.
Earnings Scheduled For July 25, 2023
Companies Reporting Before The Bell
• Unilever (NYSE:UL) is expected to report earnings for its first quarter.
• Lilium (NASDAQ:LILM) is estimated to report earnings for its first quarter.
What 7 Analyst Ratings Have To Say About AtriCure
Analysts have provided the following ratings for AtriCure (NASDAQ:ATRC) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Canaccord Genuity Maintains Buy on AtriCure, Lowers Price Target to $74
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $81 to $74.
Needham Reiterates Buy on AtriCure, Maintains $58 Price Target
Needham analyst Mike Matson reiterates AtriCure (NASDAQ:ATRC) with a Buy and maintains $58 price target.
Earnings Scheduled For February 21, 2023
Companies Reporting Before The Bell
• Sohu.com (NASDAQ:SOHU) is likely to report earnings for its fourth quarter.
Earnings Outlook For AtriCure
AtriCure (NASDAQ:ATRC) is set to give its latest quarterly earnings report on Tuesday, 2023-02-21. Here’s what investors need…
Needham Maintains Buy on AtriCure, Raises Price Target to $58
Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $58.
AtriCure Q3 EPS $(0.27) Misses $(0.25) Estimate, Sales $83.20M Beat $81.33M Estimate
AtriCure (NASDAQ:ATRC) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.25) by 8 percent. This is a 17.39 percent decrease over losses of $(0.23) per share from the same